FOCUS 05.21 – SenzaGen and VitroScreen join forces

SenzaGen and VitroScreen has decided to join forces. The highly accurate and broadly applicable skin sensitization test platform GARD will be joined by a recognized pre-clinical CRO and leading in vitro research laboratory.

By joining forces, SenzaGen and VitroScreen will be able to combine their respective knowledge and expertise in novel and advanced biological systems, genomics, proteomics and machine learning to create innovative tools to help the industry transition to animal free testing with high performance human-based technology. SenzaGen and VitroScreen will provide a broadened in vitro service portfolio ranging from in vitro toxicology to preclinical efficacy testing.


SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology. The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings.

The company´s state-of-the-art GARD® test platform combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. Its high informational content and a holistic view of the immunological responses contribute to high predictive accuracy and human relevance.

SenzaGen has its headquarters and GLP certified laboratory in Lund, Sweden, and a subsidiary in the US. Learn more about SenzaGen at